Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovag...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2022-09-01
|
| coleção: | Journal of Investigative Medicine High Impact Case Reports |
| Acesso em linha: | https://doi.org/10.1177/23247096221123144 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|